Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 62 clinical trials
Efficacy and Safety Evaluation of BCMA-UCART

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.

refractory multiple myeloma
bcma
induction therapy
  • 8 views
  • 15 Mar, 2021
  • 1 location
T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory multiple

  • 0 views
  • 16 Nov, 2021
  • 1 location
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma

Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. Genetically engineered lymphocyte (CART) therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. …

bcma
cell transplantation
cancer
leukemia
refractory multiple myeloma
  • 8 views
  • 22 Jan, 2021
  • 1 location
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

This Phase I/II study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible

bcma
platelet count
fludarabine
measurable disease
serum proteins
  • 47 views
  • 19 Feb, 2021
  • 7 locations
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have several

proteasome inhibitor
bcma
dexamethasone
measurable disease
  • 11 views
  • 26 Nov, 2021
  • 13 locations
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.

refractory multiple myeloma
remission
bcma
  • 7 views
  • 23 Jan, 2021
  • 1 location
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

bcma
fludarabine
refractory multiple myeloma
ejection fraction
immunohistochemistry
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

remission
bcma
stem cell transplantation
refractory multiple myeloma
cell transplantation
  • 0 views
  • 16 Mar, 2021
  • 1 location
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

remission
bcma
stem cell transplantation
refractory multiple myeloma
cell transplantation
  • 0 views
  • 14 Mar, 2021
  • 1 location
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR

refractory multiple myeloma
bcma
cancer
  • 24 views
  • 23 Jan, 2021
  • 1 location